Ftse Mib
34.516,04
0,16%
DAX
18.714,80
0,17%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.620,53
0,75%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ uniQure NV (QURE) uniQure NV (QURE) Notizie

QURE

uniQure NV (QURE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QURE
DataOraFonteTitoloSimboloCompagnia
07/05/202414:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/05/202413:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/05/202413:05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
05/03/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
28/02/202414:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
28/02/202413:05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/02/202422:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
13/02/202422:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202313:05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202301:30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202313:05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202313:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
07/11/202313:05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/10/202316:00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
26/10/202320:38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
26/10/202320:14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202313:05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
06/10/202312:33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
06/10/202312:32Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
05/10/202313:05GlobeNewswire Inc.uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage ProgramsNASDAQ:QUREuniQure NV
03/10/202303:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/09/202319:59Dow Jones NewsRe/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600NASDAQ:QUREuniQure NV
05/09/202313:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
02/09/202300:51PR Newswire (US)Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600NASDAQ:QUREuniQure NV
01/08/202313:05GlobeNewswire Inc.uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/06/202313:11GlobeNewswire Inc.uniQure Announces Leadership Addition to Support Advancement of Clinical ProgramsNASDAQ:QUREuniQure NV
22/06/202323:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QUREuniQure NV
21/06/202313:05GlobeNewswire Inc.uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
20/06/202323:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
20/06/202313:05GlobeNewswire Inc.uniQure announces achievement of $100 million milestone related to hemophilia B gene therapyNASDAQ:QUREuniQure NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QURE

La tua Cronologia

EU
EMSA
iShares JP Morgan ESG EM...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network